JP2016540017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540017A5 JP2016540017A5 JP2016539132A JP2016539132A JP2016540017A5 JP 2016540017 A5 JP2016540017 A5 JP 2016540017A5 JP 2016539132 A JP2016539132 A JP 2016539132A JP 2016539132 A JP2016539132 A JP 2016539132A JP 2016540017 A5 JP2016540017 A5 JP 2016540017A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- membered heterocyclic
- membered heteroaryl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 176
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 82
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 71
- 229910052736 halogen Inorganic materials 0.000 claims 52
- 150000002367 halogens Chemical group 0.000 claims 52
- 125000000753 cycloalkyl group Chemical group 0.000 claims 44
- 125000005842 heteroatom Chemical group 0.000 claims 42
- 229910052760 oxygen Inorganic materials 0.000 claims 42
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 239000001257 hydrogen Substances 0.000 claims 40
- 125000004093 cyano group Chemical group *C#N 0.000 claims 36
- 125000004043 oxo group Chemical group O=* 0.000 claims 31
- 125000001931 aliphatic group Chemical group 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 24
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 22
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 21
- 125000002723 alicyclic group Chemical group 0.000 claims 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 20
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000004429 atom Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 17
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000002619 bicyclic group Chemical group 0.000 claims 12
- 208000002815 pulmonary hypertension Diseases 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 5
- 210000002216 heart Anatomy 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 230000002685 pulmonary effect Effects 0.000 claims 5
- 230000001568 sexual effect Effects 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 230000000414 obstructive effect Effects 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000006029 Cardiomegaly Diseases 0.000 claims 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims 3
- 208000005189 Embolism Diseases 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 3
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000001746 atrial effect Effects 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 238000000502 dialysis Methods 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 230000001732 thrombotic effect Effects 0.000 claims 3
- 208000014001 urinary system disease Diseases 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 206010063985 Phytosterolaemia Diseases 0.000 claims 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 208000002227 Sitosterolemia Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 208000014731 pulmonary artery disease Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002915 Aortic valve incompetence Diseases 0.000 claims 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 208000002102 Atrial Premature Complexes Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 claims 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 1
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020575 Hyperammonaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000002682 Hyperkalemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010024119 Left ventricular failure Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000020128 Mitral stenosis Diseases 0.000 claims 1
- 208000011682 Mitral valve disease Diseases 0.000 claims 1
- 206010027727 Mitral valve incompetence Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010034487 Pericarditis constrictive Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010061340 Peripheral embolism Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims 1
- 201000001068 Prinzmetal angina Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims 1
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039163 Right ventricular failure Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000001163 Tangier disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 claims 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 claims 1
- 206010044642 Tricuspid valve stenosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000026723 Urinary tract disease Diseases 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
- 208000032594 Vascular Remodeling Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000008131 Ventricular Flutter Diseases 0.000 claims 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000002064 aortic valve insufficiency Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 210000002565 arteriole Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000003788 cerebral perfusion Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000000839 constrictive pericarditis Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 230000004089 microcirculation Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000006887 mitral valve stenosis Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000036316 preload Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 claims 1
- 210000003492 pulmonary vein Anatomy 0.000 claims 1
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims 1
- 208000030390 pulmonic stenosis Diseases 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000010451 regulation of platelet aggregation Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000015658 resistant hypertension Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 210000004003 subcutaneous fat Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 208000037820 vascular cognitive impairment Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914908P | 2013-12-11 | 2013-12-11 | |
| US61/914,908 | 2013-12-11 | ||
| US201462051539P | 2014-09-17 | 2014-09-17 | |
| US62/051,539 | 2014-09-17 | ||
| PCT/US2014/069537 WO2015089182A1 (en) | 2013-12-11 | 2014-12-10 | Sgc stimulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540017A JP2016540017A (ja) | 2016-12-22 |
| JP2016540017A5 true JP2016540017A5 (enExample) | 2018-02-01 |
Family
ID=52293206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539132A Pending JP2016540017A (ja) | 2013-12-11 | 2014-12-10 | ｓＧＣ刺激物質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20160311826A1 (enExample) |
| EP (1) | EP3092231B1 (enExample) |
| JP (1) | JP2016540017A (enExample) |
| CN (1) | CN106304835A (enExample) |
| CA (1) | CA2933250A1 (enExample) |
| EA (1) | EA032028B1 (enExample) |
| MX (1) | MX2016007522A (enExample) |
| WO (1) | WO2015089182A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33476A (es) | 2010-06-30 | 2012-02-29 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
| CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| IL285564B2 (en) | 2013-03-15 | 2024-06-01 | Cyclerion Therapeutics Inc | sGC Stimulators |
| WO2016044447A1 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
| WO2016044446A2 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20170298055A1 (en) * | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
| EP3481818B1 (en) * | 2016-07-07 | 2023-09-06 | Cyclerion Therapeutics, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| PE20190607A1 (es) | 2016-09-02 | 2019-04-23 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
| WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| CN108203396B (zh) * | 2016-12-19 | 2020-12-08 | 江西东邦药业有限公司 | 一种脑啡肽酶抑制剂的合成 |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US11897887B2 (en) * | 2017-12-19 | 2024-02-13 | Tisento Therapeutics Inc. | sGC stimulators |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| JP7542518B2 (ja) | 2018-07-11 | 2024-08-30 | ティセント セラピューティクス インコーポレーテッド | ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用 |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| US20240115545A1 (en) | 2020-10-08 | 2024-04-11 | Curome Biosciences Co., Ltd. | Pharmaceutical composition containing b-lapachone as active ingredient for prevention or treatment of cholestatic liver disease |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5366997A (en) | 1991-09-24 | 1994-11-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5650442A (en) | 1993-10-08 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DK0837052T3 (da) | 1995-06-21 | 2007-01-02 | Shionogi & Co | Bicykliske aminoderivater og PGD2-antagonist indeholdende disse |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| WO1998025915A1 (en) | 1996-12-12 | 1998-06-18 | Shionogi & Co., Ltd. | Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same |
| US6083974A (en) | 1996-12-13 | 2000-07-04 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| BR9911914B1 (pt) | 1998-07-08 | 2010-10-19 | n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas. | |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| MXPA01006108A (es) | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| JP2003530426A (ja) | 2000-04-12 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | Ｐｇｄ２受容体拮抗薬を用いるアレルギー状態の治療のための方法および組成物 |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| FR2811989A1 (fr) | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| PE20020870A1 (es) | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| US7153852B2 (en) | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
| CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| US20050059660A1 (en) * | 2003-08-01 | 2005-03-17 | Pharmacia & Upjohn Company | Novel combination |
| WO2005011634A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| US20090186896A1 (en) * | 2005-09-29 | 2009-07-23 | Bayer Healthcare Ag | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders |
| GB0604937D0 (en) | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| AU2007292347A1 (en) | 2006-09-07 | 2008-03-13 | Allergan, Inc. | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity |
| EP2101741B1 (en) | 2006-10-17 | 2010-08-11 | Bend Research, Inc. | Solid dispersion comprising a poorly water soluble drug |
| CA2686906A1 (en) * | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators, sgc activators and combinations for the treatment of urological disorders |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| EP2244575B1 (en) | 2008-01-24 | 2013-07-17 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
| JP5411300B2 (ja) | 2009-02-26 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | 可溶性グアニレートシクラーゼ活性化剤 |
| SI2531187T1 (sl) | 2010-02-05 | 2016-01-29 | Adverio Pharma Gmbh | Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze |
| WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2800541C (en) | 2010-05-27 | 2016-03-22 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| UY33476A (es) * | 2010-06-30 | 2012-02-29 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
| CN103180327B (zh) | 2010-07-09 | 2016-08-10 | 拜耳知识产权有限责任公司 | 稠环的4-氨基嘧啶及其作为可溶性鸟甘酸环化酶的刺激物的用途 |
| US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| RU2016101964A (ru) * | 2010-11-09 | 2018-11-21 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
| US9012651B2 (en) | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
| JP6109161B2 (ja) | 2011-07-06 | 2017-04-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ヘテロアリール置換ピラゾロピリジン類およびその使用 |
| WO2013030288A1 (de) | 2011-09-02 | 2013-03-07 | Bayer Intellectual Property Gmbh | Substituierte annellierte pyrimidine und ihre verwendung |
| EP2794596B1 (en) * | 2011-12-21 | 2017-05-31 | Bayer Intellectual Property GmbH | Substituted benzylpyrazoles |
| EP3112363A1 (en) * | 2011-12-27 | 2017-01-04 | Ironwood Pharmaceuticals, Inc. | 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension |
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| IL285564B2 (en) * | 2013-03-15 | 2024-06-01 | Cyclerion Therapeutics Inc | sGC Stimulators |
| JP2016522232A (ja) * | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロアリール置換されたピラゾール類 |
-
2014
- 2014-12-10 US US15/103,178 patent/US20160311826A1/en not_active Abandoned
- 2014-12-10 CN CN201480074810.XA patent/CN106304835A/zh active Pending
- 2014-12-10 WO PCT/US2014/069537 patent/WO2015089182A1/en not_active Ceased
- 2014-12-10 CA CA2933250A patent/CA2933250A1/en not_active Abandoned
- 2014-12-10 EA EA201691194A patent/EA032028B1/ru not_active IP Right Cessation
- 2014-12-10 JP JP2016539132A patent/JP2016540017A/ja active Pending
- 2014-12-10 MX MX2016007522A patent/MX2016007522A/es unknown
- 2014-12-10 EP EP14824644.0A patent/EP3092231B1/en active Active
-
2020
- 2020-12-15 US US17/122,542 patent/US20210214364A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540017A5 (enExample) | ||
| JP2019526582A5 (enExample) | ||
| JP2016517432A5 (enExample) | ||
| JP2019524710A5 (enExample) | ||
| HRP20200276T1 (hr) | Stimulatori sgc | |
| HRP20211355T1 (hr) | Fuzionirani biciklični sgc stimulatori | |
| JP2012532112A5 (enExample) | ||
| RU2013125480A (ru) | Стимуляторы sgc | |
| CN102256984B (zh) | 制备二胺衍生物的方法 | |
| JP5165748B2 (ja) | イミダゾリジノン誘導体 | |
| CN106459076B (zh) | 用于诱导软骨发生的化合物和组合物 | |
| JP2017527604A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| PT2007752E (pt) | Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4 | |
| JP2007529484A5 (enExample) | ||
| RU2010149611A (ru) | Ациламинозамещенные производные конденсированных циклопентанкарбоновых кислот и их применение в качестве фармацевтических средств | |
| KR20200120930A (ko) | 헤테로시클릭 화합물, 이의 응용 및 이를 포함하는 의약 조성물 | |
| JP2019525915A5 (enExample) | ||
| MX2007009592A (es) | Terapia de combinacion. | |
| JP2013520407A (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としてのピラゾロピペリジン誘導体 | |
| JP2013535424A5 (enExample) | ||
| JP2013533250A5 (ja) | 環縮合４−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用 | |
| KR20170094263A (ko) | Ｎａｄｐｈ 옥시다제 억제제인 아미도 티아디아졸 유도체 | |
| CN112638877B (zh) | 用于治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物 | |
| JP2013519724A (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としてのピラゾロピペリジン誘導体 |